NASDAQ:DRMA Dermata Therapeutics (DRMA) Stock Price, News & Analysis $0.77 0.00 (-0.55%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dermata Therapeutics Stock (NASDAQ:DRMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dermata Therapeutics alerts:Sign Up Key Stats Today's Range$0.74▼$0.7850-Day Range$0.71▼$1.4252-Week Range$0.69▼$5.00Volume12,844 shsAverage Volume1.17 million shsMarket Capitalization$4.89 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingBuy Company OverviewDermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Read More… Dermata Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreDRMA MarketRank™: Dermata Therapeutics scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingDermata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageDermata Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Dermata Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Dermata Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dermata Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDermata Therapeutics has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.76% of the float of Dermata Therapeutics has been sold short.Short Interest Ratio / Days to CoverDermata Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dermata Therapeutics has recently increased by 110.83%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDermata Therapeutics does not currently pay a dividend.Dividend GrowthDermata Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.76% of the float of Dermata Therapeutics has been sold short.Short Interest Ratio / Days to CoverDermata Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dermata Therapeutics has recently increased by 110.83%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Dermata Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dermata Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.40% of the stock of Dermata Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 8.67% of the stock of Dermata Therapeutics is held by institutions.Read more about Dermata Therapeutics' insider trading history. Receive DRMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DRMA Stock News HeadlinesDermata’s XYNGARI trial hits statistically significant difference at 4 weeksApril 17, 2025 | markets.businessinsider.comDermata Therapeutics files to sell 10.01M shares of common stock for holdersApril 17, 2025 | markets.businessinsider.comThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or vaults. It's quiet. Slow. And it's targeting your retirement. The U.S. government has racked up over $36 trillion in debt, and their solution?May 22, 2025 | American Hartford Gold (Ad)Dermata Therapeutics: Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference at 4 WeeksApril 15, 2025 | finanznachrichten.deDermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 WeeksApril 15, 2025 | finance.yahoo.comDermata Therapeutics’ xyngari in acne meets all primary Phase 3 endpointsMarch 28, 2025 | markets.businessinsider.comDermata Therapeutics Shares Surge on Positive Acne Treatment StudyMarch 27, 2025 | marketwatch.comNano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For AcneMarch 27, 2025 | benzinga.comSee More Headlines DRMA Stock Analysis - Frequently Asked Questions How have DRMA shares performed this year? Dermata Therapeutics' stock was trading at $1.35 at the beginning of 2025. Since then, DRMA shares have decreased by 42.9% and is now trading at $0.7702. View the best growth stocks for 2025 here. How were Dermata Therapeutics' earnings last quarter? Dermata Therapeutics, Inc. (NASDAQ:DRMA) issued its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.45) earnings per share for the quarter, meeting the consensus estimate of ($0.45). When did Dermata Therapeutics' stock split? Shares of Dermata Therapeutics reverse split on Thursday, May 16th 2024. The 1-15 reverse split was announced on Thursday, May 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Dermata Therapeutics IPO? Dermata Therapeutics (DRMA) raised $18 million in an initial public offering (IPO) on Friday, August 13th 2021. The company issued 2,571,428 shares at a price of $7.00 per share. Who are Dermata Therapeutics' major shareholders? Dermata Therapeutics' top institutional investors include Armistice Capital LLC (6.81%). How do I buy shares of Dermata Therapeutics? Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dermata Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dermata Therapeutics investors own include BIOLASE (BIOL), CNS Pharmaceuticals (CNSP), Esports Entertainment Group (GMBL), Jiuzi (JZXN), Kiora Pharmaceuticals (KPRX), ENDRA Life Sciences (NDRA) and Sonnet BioTherapeutics (SONN). Company Calendar Last Earnings5/14/2025Today5/21/2025Next Earnings (Estimated)5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DRMA CIK1853816 Webwww.dermatarx.com Phone858-800-2543FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+289.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($16.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-247.39% Return on Assets-179.72% Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio3.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$24.24 per share Price / Book0.03Miscellaneous Outstanding Shares6,378,000Free Float1,849,000Market Cap$4.91 million OptionableNot Optionable Beta0.59 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:DRMA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.